Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q1 2022 · 10-Q
Revenue—
Net Income-$4.60M-$4.60MN/M vs Q1 2021 EPS Diluted-$0.12-$0.12N/M vs Q1 2021 Operating Income-$4,594,000N/M Operating Cash Flow-$4,996,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end